Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter (Q4) of Fiscal Year 2019
Filing Date: May 1, 2019
This filing serves as a notification of the Company's Q4 FY2019 results. The full financial details are contained in Exhibit 99.1, which is referenced but not included in the provided text.
Key Financial Metrics
The provided text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached "Q4 FY2019 Results Notification" (Exhibit 99.1), which is not part of the input content.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the provided text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes extensive disclosures regarding forward-looking statements covering future performance, capital expenditures, credit facilities, dividends, and share buy-backs.
Key Risks and Contingencies:
- Asbestos Liability: Risks related to prior asbestos product manufacture, contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls in the AICF, and currency exchange impacts on asbestos liabilities.
- Legal and Regulatory: Exposure to product liability, environmental, and consumer class action proceedings.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, and consumer confidence.
- Operational: Integration of Fermacell, supply chain costs, and potential plant closures or suspensions.
- Financial: Currency exchange risks and the ability to renew credit facilities on favorable terms.
Investor Verification Checklist
- Review Exhibit 99.1 ("Q4 FY2019 Results Notification") for actual revenue, earnings, and cash flow figures.
- Verify the status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF).
- Assess the impact of currency exchange rates on reported financial results and asbestos liabilities.
- Monitor the integration progress of the Fermacell acquisition.
- Check for updates on pending legal proceedings and warranty provision estimates.